Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD8+ Memory T Cell Infusion in Allogeneic HCT
NCT04151706Phase 2Completed
- Start
- Feb 2020
- Primary completion
- Sep 2023
- Modality
- Allogeneic CAR-T, Tumor-Infiltrating Lymphocytes (TILs), TCR-Engineered T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of allogeneic cd8+ memory t-cells in myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML). Started Feb 2020; status: completed.
02
Drugs
allogeneic cd8+ memory t-cells
03
Conditions
myelodysplastic syndrome (MDS)acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT04151706.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04151706.